Knoll Pharmaceutical Co.

Much of the attention coming out of AbbVie Inc. 's earnings call Jan. 25 was focused on the company's reduction of ex-US revenue estimates for top-seller Humira (adalimumab) for the second time in

External sourcing of pipeline assets is increasing overall within big pharma, but there is significant variation among the sector's companies, according to a new report from Datamonitor Healthcare.

A regular roundup of company developments in Turkey. For the previous article in the series, see ( [A#28151213003] ). Baxter-Eczacibasi Partnership Changes Baxter International Inc. ’s business and

FDA will be hard-pressed to replace the institutional knowledge and regulatory expertise on weight-management drugs lost with the recent passing of Division of Metabolism and Endocrinology Products De